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ABSTRACT CRISPR-Cas immune systems adapt to new threats by acquiring new
spacers from invading nucleic acids such as phage genomes. However, some CRISPR-
Cas loci lack genes necessary for spacer acquisition despite variation in spacer content
between microbial strains. It has been suggested that such loci may use acquisition
machinery from cooccurring CRISPR-Cas systems within the same strain. Here, follow-
ing infection by a virulent phage with a double-stranded DNA (dsDNA) genome, we
observed spacer acquisition in the native host Flavobacterium columnare that carries
an acquisition-deficient CRISPR-Cas subtype VI-B system and a complete subtype II-C
system. We show that the VI-B locus acquires spacers from both the bacterial and
phage genomes, while the newly acquired II-C spacers mainly target the viral genome.
Both loci preferably target the terminal end of the phage genome, with priming-like
patterns around a preexisting II-C protospacer. Through gene deletion, we show that
the RNA-cleaving VI-B system acquires spacers in trans using acquisition machinery
from the DNA-cleaving II-C system. Our observations support the concept of cross talk
between CRISPR-Cas systems and raise further questions regarding the plasticity of ad-
aptation modules.
IMPORTANCE CRISPR-Cas systems are immune systems that protect bacteria and
archaea against their viruses, bacteriophages. Immunity is achieved through the ac-
quisition of short DNA fragments from the viral invader’s genome. These fragments,
called spacers, are integrated into a memory bank on the bacterial genome called
the CRISPR array. The spacers allow for the recognition of the same invader upon
subsequent infection. Most CRISPR-Cas systems target DNA, but recently, systems
that exclusively target RNA have been discovered. RNA-targeting CRISPR-Cas systems
often lack genes necessary for spacer acquisition, and it is thus unknown how new
spacers are acquired and if they can be acquired from DNA phages. Here, we show
that an RNA-targeting system “borrows” acquisition machinery from another CRISPR-
Cas locus in the genome. Most new spacers in this locus are unable to target phage
mRNA and are therefore likely redundant. Our results reveal collaboration between
distinct CRISPR-Cas types and raise further questions on how other CRISPR-Cas loci
may cooperate.
KEYWORDS CRISPR, adaptation, bacteriophages, coevolution, spacer acquisition,
type II, type VI
CRISPR (clustered regularly interspaced short palindromic repeat) arrays consistof multiple nucleotide repeats separated by variable spacer sequences (1). The
repeats and spacers, together with Cas (CRISPR-associated) genes/proteins (2), consti-
tute the CRISPR-Cas systems that protect bacteria and archaea against infections by
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bacteriophages (phages) (3). CRISPR-Cas systems are divided into six types and several
subtypes on the basis of their cas gene composition (4). Immunity operates through
three main phases: adaptation, expression, and interference. In the adaptation (or ac-
quisition) phase, a fragment from the phage genome (protospacer [5]), usually next to
a protospacer-adjacent motif (PAM) (6), is inserted into a CRISPR array as a spacer. New
spacers are usually inserted into the array in a polarized fashion so that one end of the
array (called the variable end) accumulates the most recent spacers. The variable
CRISPR end is adjacent to the AT-rich region called the leader sequence (2, 3, 5, 7). In
the expression phase, the array is transcribed (usually initiated from a promoter in the
leader sequence and progressing toward the array) and processed to produce short
CRISPR RNAs (crRNAs). These RNA fragments, each consisting of a complete or partial
single spacer and repeat, guide endonucleases to complementary sequences on the
invading phage genome in the interference phase (8–10). Most types of CRISPR-Cas
systems target DNA, but type VI systems target RNA, while type III systems target both
nucleic acids (4). Upon recognizing the PAM sequence (or the shorter protospacer-
flanking site [PFS] in type VI systems [11]) and binding to the target, the target is
cleaved, curing the host of infection.
Adaptation is almost universally mediated by a complex consisting of Cas1 and
Cas2 that may recruit additional proteins depending on the subtype. For example,
type I-D requires Cas4 for correct adaptation (12), while type II-A recruits Csn2 and
Cas9 for successful recognition of the spacer acquisition motif (SAM) (13–15). The SAM
is sometimes used to denote the PAM during acquisition, as it may differ from the in-
terference-related PAM, also called the target interference motif (TIM) (13). Some sub-
type III-B systems acquire spacers from RNA using a Cas1 fused to a reverse transcrip-
tase (16), which has also been predicted for some type VI-A systems (17).
Spacer acquisition generally occurs through either naive or primed adaptation.
Naive adaptation occurs when no preexisting spacers target the incoming genome
(18), while primed adaptation benefits from partially or fully matching preexisting
spacers (19–22). Priming has been generally studied in class I systems, but recent anal-
yses suggest that priming may be widespread in type II systems (23) and has experi-
mentally been shown in subtype II-A (24). Type II-A priming relies on Cas9-mediated
cleavage through a perfectly matching spacer and its target, leading to the production
of free DNA ends that are used as material for spacer acquisition (24, 25).
Regardless of the composition of the adaptation complex, the insertion of new
spacers requires interaction between the acquisition complex and the CRISPR array’s
leader-repeat junction (18). This interaction relies on conserved sequences in the lead-
ers and repeats. In the subtype II-A system of Streptococcus thermophilus, the conserva-
tion of the first 10 nucleotides on both sides of the leader-repeat junction is essential
for spacer integration (26), as is the conservation of the first 41 to 43 nucleotides of the
leader in the Escherichia coli subtype I-E system (18, 27). Subtype I-D leaders also con-
tain conserved nucleotides that are more distant from the leader-repeat junction (28).
As repeats and leaders vary in sequence and length, their respective adaptation pro-
teins have coevolved accordingly (13, 29–32). Therefore, CRISPR-Cas systems cooccur-
ring within a genome have distinct versions of Cas1 and Cas2 (and possibly other ac-
quisition-related proteins), restraining their capacity to function on other leaders and
repeats. Surprisingly, some bacterial isolates contain CRISPR-Cas systems that lack ad-
aptation modules but still have variable spacer contents (13, 33–36). Such systems may
engage in cross talk between other intragenomic CRISPR-Cas loci by utilizing their ad-
aptation machinery in trans (33, 37–41). In Sulfolobus solfataricus, in trans acquisition is
supported by an acquisition-deficient subtype III-B locus that can still acquire spacers
with PAMs matching those of a cooccurring type I system with similar CRISPR sequen-
ces (35). Other examples are acquisition-deficient plasmid-encoded subtype IV-A3 loci
that frequently cooccur with host-encoded subtype I-E systems and share similarities
with their leader, repeat, and PAM sequences (36). Cross talk between different
CRISPR-Cas systems has been shown in the expression (42) and interference (43)
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phases, but the evidence for in trans-mediated spacer acquisition between CRISPR-Cas
systems is still indirect, awaiting experimental verification.
The recently discovered type VI CRISPR-Cas systems (11, 37, 39) often lack Cas1/2
(4) and thus have been proposed to acquire spacers in trans (37, 39–41). However, as
type VI loci exclusively target RNA, obtaining spacers from double-stranded DNA
(dsDNA) (the modus operandi for most acquisition complexes) is not optimal, as only
half of the potential spacers may functionally target mRNAs. Adaptation in type VI sys-
tems has yet to be experimentally demonstrated, and it is unknown if new spacers are
acquired through the in trans adaptation model and, if so, how this affects their
capacity to target RNA.
The genome of the fish pathogen Flavobacterium columnare has subtype II-C and
VI-B CRISPR-Cas loci (Fig. 1). The II-C locus contains the adaptation proteins Cas1 and
Cas2 and the endonuclease Cas9 that cleaves dsDNA (although some Cas9 variants
also cleave single-stranded RNA [ssRNA] [44, 45]). The II-C locus of F. columnare also
contains genes encoding a predicted ParDE type II toxin-antitoxin system between
cas9 and the repeat-spacer array, which may contribute to the immune response (46,
47). II-C systems differ from other CRISPR-Cas systems by the expression of their array
from repeat-encoded promoters instead of the leader sequence (44, 48). Subtype VI-B
of F. columnare encodes only Cas13b and does not contain adaptation genes, nor does
it contain csx27 or csx28 that is often associated with type VI-B systems (4). Cas13 exclu-
sively cleaves RNA and is guided to its target by its bound crRNA, similar to other inter-
ference complexes. However, once activated by this primary target, Cas13 becomes a
promiscuous RNase that also cleaves noncomplementary phage and host transcripts,
potentially leading to cellular dormancy or death (11, 39, 49).
Previously, we showed that natural isolates of F. columnare vary in their phage-tar-
geting spacer contents in both loci, driving the evolution of sympatric phages (34).
Only the phage mRNA strand was targeted by VI-B spacers (n=15), while this was the
case for only half of the II-C protospacers (34). While the accumulation of mRNA-target-
ing spacers in the VI-B locus was clear, it is unknown if this was due to a selective
spacer acquisition process or from positive selection due to successful interference. To
further characterize spacer acquisition in these loci, we cocultured F. columnare with a
virulent dsDNA phage under laboratory conditions (Fig. 2). Our results revealed details
FIG 1 Comparison of the arrangements of II-C and VI-B CRISPR-Cas loci in F. columnare B185. Colored boxes represent spacers, and diamonds represent
repeats (T denotes the terminal repeat). Repeats and leaders are aligned with no gaps and presented in the 59-to-39 direction (base 36 in repeats is leader
proximal). Genomic positions are given according to the F. columnare B185 genome (GenBank accession no. NZ_CP010992.1). The gray arrows show the
directions of transcription that are inferred from previous studies, the presence of putative promoters, and our transcriptome data. The II-C locus also
contains the predicted toxin-antitoxin genes parD and parE. To make comparisons of the loci easier, both loci are displayed with the leader in the 39 end.
The putative II-C trans-activating crRNA (tracrRNA) has not been experimentally validated.
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of subtype VI-B and II-C adaptation in a native host as well as the first experimental evi-
dence of in trans adaptation between CRISPR-Cas types despite differences in leader
and repeat sequences.
RESULTS
Phage-induced acquisition in both loci. To study the adaptation phase of subtype
II-C and VI-B loci in a controlled environment, we cultured F. columnare strain B185 (50,
51) (GenBank accession no. NZ_CP010992.1) with its virulent dsDNA phage FCL-2
(accession no. NC_027125.1) (51) in liquid medium (bacterium plus phage [B1P] treat-
ment) (Fig. 2). We also included treatments with UV-irradiated phage FCL-2 (bacteria
plus UV-phage [B1UVP]) and a mixture of irradiated and nonirradiated phages
(B1P1UVP). The addition of defective UV-treated phages has been shown to increase
spacer acquisition in subtype II-A (52). The native II-C CRISPR array of F. columnare
B185 contains four preexisting spacers targeting the genome of phage FCL-2 and four
VI-B spacers with imperfect matches to FCL-2 (see Table S3A and B in the supplemental
material). After a week of coculturing, we plated the liquid cultures to screen for
expanded CRISPR arrays in individual colonies (total of 272 colonies screened)
(Table S1). Only bacteria that were exposed to the phage mixture (B1P1UVP) had
acquired new spacers (14 out of 85 colonies). We did not observe spacer acquisition in
bacteria that were not exposed to phage (B) or that were exposed to either phage
treatment alone (B1P or B1UVP) (Tables S1 and S2).
Next, we focused on CRISPR adaptation at the bacterial population level by amplify-
ing by PCR the variable ends of both arrays directly from the same liquid cultures. In
contrast to individual colony screening, we observed spacer acquisition in both the
phage mixture treatment (B1P1UVP) (data not shown) and the phage-only treatment
(B1P) (Fig. S1). The difference between the individual-colony screening and popula-
tion-level screening likely stems from the higher sensitivity of the latter. All down-
stream analyses were done on the B1P samples, as this treatment is closer to a natural
scenario (UV irradiation lowers phage infectivity by 2 orders of magnitude). Within
each replicate of the B1P treatment (identified as replicates a to e), the relative rates
FIG 2 Overview of the acquisition experiment. Spacer acquisition in F. columnare strain B185 (B) was
investigated using a two-step growth method in diluted and undiluted media. Bacterium plus phage
FCL-2 (B1P) treatment was accompanied by a phage mixture containing UV-treated phages
(B1P1UVP) and UV-treated phages alone (B1UVP), all done in 5 replicates (a to e). Spacers were
examined in individual colonies from all three phage-based treatments as well as by deep
sequencing of the CRISPR arrays in the B1P treatment. “Failed amplification” refers to samples where
the DNA yield from expanded arrays was insufficient for sequencing.
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of spacer acquisition were similar between the two arrays (Fig. S1). To identify the di-
versity and origin of the new CRISPR spacers, we deep sequenced the population-scale
variable ends of the CRISPR arrays. We obtained data on new II-C spacers in replicates
b and e and on VI-B spacers in replicates b, d, and e (other replicates did not allow for
deep sequencing due to low DNA yields). PCR amplicons in the wild-type control cul-
tures were also sequenced to ensure that the arrays had remained unchanged.
The lengths of new spacers varied between 28 and 32 bp, with the majority at
30 bp in both loci (Fig. 3A). We divided the new spacers into unique and absolute sets.
In the unique spacer data set, each spacer sequence was counted only once, whereas
the absolute set allowed for repeated observations of the same spacer. Most unique II-
C spacers targeted the phage genome, with a minority targeting the bacterial genome
(Fig. 3B). New VI-B spacers targeted both genomes relatively evenly, although the repli-
cates had some differences (Fig. 3B). All differences were accentuated when the spacer
count was viewed as absolute (Fig. 3C). The distinct targeting preferences between the
loci are likely explained by the negative selection of autoimmunity resulting from
Cas9-mediated self-targeting (e.g., see reference 53). The lowered fitness due to self-
FIG 3 Analysis of acquired spacers in the coculture experiment. (A) Size distribution of unique spacers in different replicates. (B) Proportions of unique
subtype II-C or VI-B spacers targeting the phage or bacterial (self) genome. Dots show the exact counts of spacers in a replicate (b, d, or e), and bars show
their respective means. (C) Similar to panel B but showing proportions using absolute spacer counts. (D) Efficiency of conjugation (number of conjugants
per recipient cell) normalized to the mean of the nonmatching control treatment. (E) F. columnare conjugants on antibiotic agar plates. Cells were
conjugated with either a plasmid containing a protospacer matching the most recent II-C spacer or a plasmid containing a nonmatching control sequence.
All three replicate plates per treatment are shown, with one replicate enlarged. (F) Proportions of simulated and observed VI-B spacers that are identical to
the II-C spacer pool. (G) PAM sequences next to II-C and VI-B phage targets (sequences from the nontarget strand; example from replicate e) (for all
replicates, see Fig. S2A in the supplemental material).
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targeting in II-C is further implied by the proportional reduction of self-targeting
spacers in the absolute data set (Fig. 3C) compared to the unique set (Fig. 3B). The
abundance of self-targeting VI-B spacers was surprising given that such spacers could
induce dormancy and be negatively selected (49). The observed pattern therefore indi-
cates that, at least during this 7-day experiment, self-targeting VI-B spacers were not
necessarily harmful.
To confirm that II-C spacers yield functional interference, we performed a plasmid
interference assay. We modified plasmid pAS43 (54) to include a protospacer that
matches the leader-adjacent II-C spacer in the conjugation-capable F. columnare strain
B245. As a control plasmid, we replaced the matching protospacer sequence with a
nonmatching sequence. Using Escherichia coli as the donor, the efficiency of conjuga-
tion was roughly three times lower in the matching protospacer treatment than in the
control treatment under antibiotic selection (P=0.0016; t4 = 7.62 [by an unpaired t
test]) (Fig. 3D). Surviving colonies with the matching protospacer plasmid also had a
reduced colony size (Fig. 3E). The II-C system in F. columnare seems to grant partial im-
munity to mobile genetic elements, leading to slower bacterial growth, at least when
the CRISPR target is associated with positive selection (here, an antibiotic resistance-
conferring plasmid). As speculated to occur with Listeria monocytogenes, small colonies
may result from low Cas9 expression, allowing the persistence of a small number of
plasmids in the cell (55).
To calculate the proportions of identical new spacers between the loci, we pooled
unique phage-targeting spacers from both loci from all replicates. Remarkably, 58% of
VI-B spacers were also found in the larger II-C spacer pool, suggesting that the loci
share a predisposition toward a set of spacers. For statistical comparison, we simulated
spacer acquisition across the phage genome by sampling random positions either
freely or next to predicted PAM sites (59-NNNNNTAAA-39) (n=1,528) (described in
detail below). Both simulations were run 1,000 times, with each run sampling 430
spacer positions (the size of the VI-B spacer pool). We calculated the proportions of
shared spacers between each run and the II-C spacers and found that on average, 6.3%
(standard deviation [SD], 1.2%) of the random spacers and 29.6% (SD, 1.85%) of the
PAM-adjacent spacers had a match in the subtype II-C spacer set (Fig. 3F). The similarity
between the observed VI-B and II-C sets of spacers is significantly higher than that
between either simulated pool and II-C spacers (P, 10210 by a one-tailed test), which
suggests that new spacers are sampled from a limited protospacer pool that is com-
mon to both loci.
Shared acquisition motifs suggest in trans adaptation. To further characterize
the protospacers, we investigated PAM sequences for both loci. We used the guide-ori-
ented approach that considers PAMs to be on the strand that matches a particular
spacer’s crRNA (56), i.e., on the nontarget strand. It is necessary to establish the direc-
tion of crRNA transcription before evaluating the PAM sequence as the transcription
direction determines the resulting crRNA strandedness. Previous studies have shown
that unlike other CRISPR-Cas systems, subtype II-C arrays are expressed from within the
array toward the variable end using repeat-encoded promoter sequences (59-TAAAT-
39) (44, 48). The F. columnare II-C repeats lack this sequence but have a 59-TTG-39 motif
33 bp upstream of each spacer. As the sequence TTG is an established 233 promoter
in Flavobacterium hibernum (57), this putative promoter may also drive II-C array tran-
scription in F. columnare. This direction of transcription is also supported by our tran-
scriptome data showing within-array transcripts that proceed toward the leader (albeit
with only eight reads mapping on the array [Fig. S3A]). The subtype VI-B array, on the
other hand, shows an abundance of transcripts occurring in the leader-to-array direc-
tion (Fig. S3B), as typically observed for CRISPR-Cas systems (11, 39), and has no puta-
tive repeat-encoded promoters.
In subtype II-C, the previously reported PAM (34, 58) NNNNNTAAA was observed
downstream of most (;63%) phage-targeting spacers (Fig. 3G and Fig. S2A). In the few
self-targeting subtype II-C spacers, the canonical PAM either was almost always absent
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or had extended or shortened N regions (Fig. S2B). This deprecation of the PAMs fur-
ther suggests negative selection against functional self-targeting II-C spacers and indi-
cates that both the nucleotide motif 59-TAAA-39 and the length of the N region in the
PAM play a role in subtype II-C interference in F. columnare (Fig. S2B). The protospacers
targeted by subtype VI-B had the same PAM sequence in the reverse complement
(TTTANNNNN) and located upstream (Fig. 3G), with slightly less conservation (;50%)
than the subtype II-C protospacers (Fig. S2B). Self-targeting VI-B spacers did not have
deprecated PAMs similar to the self-targeting II-C spacers, suggesting that PAMs do
not affect VI-B functionality.
When using the guide-oriented approach, the PAMs of II-C and VI-B targets are
complementary to each other and on opposite sides of the protospacer. For both loci,
the PAM-adjacent ends of the spacers are oriented toward the leader. Therefore, while
the target interference motif (TIM) of the loci is seemingly different, the spacer acquisi-
tion motif (SAM) is shared by the loci. The term TIM is not strictly applicable to the
studied RNA-targeting type VI systems, and their interference efficiency has instead
been shown to be affected by short protospacer-flanking sites (PFSs) (11, 39). Here,
conserved PFSs were not discovered in the VI-B targets. Overall, these results suggest
that the arrays likely share spacer acquisition machinery, as SAMs are generally hall-
marks of specific acquisition complexes (12, 14).
Spacer target distributions are nonuniform and show possible II-C priming.We
investigated which regions of the genomes are targeted by II-C and VI-B spacers. To do
this, we examined both unique and absolute spacer counts separately. Despite the rel-
atively even distribution of predicted PAM sequences (59-NNNNNTAAA-39) across the
phage genome (Fig. 4), spacer targets were not uniformly spread. On the linear phage
FIG 4 Distribution of spacers on the phage and bacterial genomes. The genomes are divided into bins (each
spanning 3% of the genomes), whose proportions of spacer targets are shown on the y axes by bars (bar
colors indicate different replicates, and “F targets” and “R targets” refer to the two DNA strands of the
genomes). The black line indicates the smoothed average of targeting across replicates. The red line shows the
relative frequency of the putative PAM sequence. Red markers are spacers that preexist in strain B185:
diamonds target mRNA, and circles do not. Filled markers are spacers with perfect matches and PAMs, while
nonfilled markers are spacers with 1- to 3-bp mismatches with their target sequence. (A) All spacers (absolute
count) mapped on both genomes. (B) Unique spacers mapped on both genomes.
CRISPR-Cas Adaptation in an RNA-Targeting System ®
March/April 2021 Volume 12 Issue 2 e03338-20 mbio.asm.org 7
 on M






































genome, spacer targets were concentrated in the opposite end of the genome relative
to the morphogenesis genes (59) and are therefore likely targeting the end of the ge-
nome that first enters the cell (Fig. 4). Furthermore, the two strands of the dsDNA
phage genome were targeted unevenly, with stronger differences at the end of the ge-
nome (downstream of ;30 kbp), especially in the absolute spacer set. These distribu-
tions are not explained by uneven PAM distributions on the phage genome (Fig. 4) or
between the strands (the proportions of the 1,672 instances of the PAM sequence 59-
TAAA-39 on the coding and template strands are 50.7% and 49.3%, respectively).
Intriguingly, the nonunique II-C spacers peak around a preexisting, fully matching
II-C spacer on the phage genome (Fig. 4A) (around 40 kb), a trend not visible in the
unique spacer set (Fig. 4B). The congregation of new spacers around a preexisting one
may result from CRISPR-Cas type II primed adaptation (24), where spacers are acquired
from the free dsDNA ends produced by Cas9 cleavage (25). Furthermore, the distribu-
tion of new spacers around this protospacer resembles an asymmetric pattern that is
characteristic of primed adaptation in subtype I-F CRISPR-Cas systems (21, 22). It is
unclear why the three additional phage-targeting II-C spacers (Table S3A) with canoni-
cal PAM sequences do not give rise to similar priming-like patterns (Fig. 4A). It is also
unclear why the VI-B spacers do not form similar patterns, as the production of free
dsDNA ends by Cas9 cleavage is expected to provide spacer material with no intrinsic
bias toward any specific array.
Another possibility, not mutually exclusive with priming, is that targeting the termi-
nal end of the linear phage genome that first enters the cell is predominant, as shown
with the Staphylococcus pyogenes subtype II-A system (25). In phage FCL-2, the localiza-
tion of the morphogenesis genes at the opposing end of the linear genome (59) sug-
gests that the preferred targeted end is indeed the first to enter the cell. Natural sam-
ples of F. columnare also show consistent targeting of this end in other (genetically
very similar) phage genomes (34). It is possible that primed adaptation and higher ex-
posure to spacer sampling at this end of the phage genome cooccur, perhaps explain-
ing why the three additional II-C spacers do not attract priming. In addition, if priming
played no role in F. columnare adaptation, we would expect spacers to cluster at the
very end of the genome instead of the currently observed priming-like peak approxi-
mately 10 kb from the end (Fig. 4A).
On the bacterial genome, VI-B spacers and the few II-C spacers congregated on two
asymmetric hot spots (Fig. 4). One was centered on the subtype II-C CRISPR-Cas locus,
while the other localized on the predicted origin of replication (oriC). Acquisition peaks
on oriC were previously reported in self-targeting E. coli spacers, resulting from the fre-
quent occurrence of double-stranded breaks in this region and the subsequent actions
of the RecBCD dsDNA repair complex (60). The resulting prespacer substrates are over-
represented around oriC because this region is the first to be replicated and becomes
enriched in a replicating cell. Acquisition peaks on CRISPR arrays were also docu-
mented previously (22, 60) and were speculated to arise from frequent nicking of DNA
during spacer acquisition, as nicking of the chromosome would also stall the replica-
tion fork, leading to increased spacer acquisition (60). Why spacers do not congregate
on the F. columnare VI-B locus is unclear.
Most spacers are not targeting mRNAs. To investigate if the new spacers reflect
the different target requirements of the loci (DNA versus RNA), we examined the ability
of each spacer crRNA to bind mRNA by assessing their complementarity to predicted
open reading frames (ORFs) from both target genomes. Spacers from all replicates
within a locus were also pooled for an overall estimate. For statistical context, we calcu-
lated the probabilities of mRNA-targeting proportions in both loci with a binomial dis-
tribution that uses sample sizes matching those of the pooled spacers and assumed an
equal probability of targeting each strand. Deviation from these expected distributions
signals possible bias toward or away from mRNA targeting.
In the VI-B system, when considering unique spacers, the proportion of phage
mRNA-targeting VI-B spacers was 0.46 (P= 0.074 by a one-tailed test), suggesting a
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weak or nonexistent bias toward non-mRNA-targeting spacers. VI-B mRNA targeting
on the bacterial genome was rarer and significantly below expectation at 0.359
(P, 1029 by a one-tailed test) (Fig. 5A). When considering the total spacer counts, the
proportion of phage mRNA-targeting VI-B spacers rose to 0.53 (above expectation)
(P=0.0059 by a one-tailed test) (Fig. 5B), suggesting possible enrichment of mRNA-tar-
geting spacers. On the bacterial genome, the mRNA-targeting proportions of absolute
spacers were significantly below expectation at 0.348 (P= 10210 by a one-tailed test)
(Fig. 5B).
Subtype II-C mRNA-targeting proportions in the unique spacer set were the same
for both target genomes (0.37 and 0.37). Given their vastly different sample sizes, the
proportion of mRNA-targeting spacers on the phage genome was significantly below
expectation (P, 10210 by a one-tailed test), while self-targets were not clearly biased
(P=0.052 by a one-tailed test) (Fig. 5A). In the total spacer counts, the divergence of
self-targeting II-C proportions may seem radical (Fig. 5B) but stem from the very small
sample sizes, where a slight overrepresentation of a spacer may disproportionally skew
the result by chance. Furthermore, the pooled II-C self-targeting spacers do not statisti-
cally deviate from expectation (P= 0.124 by a one-tailed test). The proportions of
FIG 5 mRNA targeting in both CRISPR loci. y axes show the proportions of spacers complementary
to predicted ORF mRNAs. Small dots are replicate cultures, and larger circles are the replicates
pooled. Binomial distributions on the right side show the spread of expected values adjusted for the
size of each spacer pool (yellow, phage; gray, host). The 95% confidence intervals of these expected
values are projected on the graph with the same color coding. Deviations from these expected
distributions suggest biased targeting. (A) Unique spacers. (B) Absolute spacer counts.
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absolute phage-targeting II-C spacers were slightly lower than in unique counts, at
0.319, and deviated strongly from expectation (P, 10210) (Fig. 5B).
The minimal phage mRNA targeting in subtype II-C spacers was unexpected, as
Cas9 functionality is indifferent to which strand is being targeted. One potential ex-
planation would be a strongly uneven distribution of PAM sequences on the coding
versus template strands, but this is not the case in either genome: the proportions of
PAM sequences (59-TAAA-39) in annotated coding sequences from B185 are 51.2%/
48.8% (coding/template) (n= 81,490), and the proportions are 51.6%/48.4% for FCL-2
(n= 1,528). Another possibility is that competition between RNA and DNA targets for
Cas9 association would impact subtype II-C immunity negatively.
The lack of new VI-B self-mRNA-targeting spacers is expected due to their possible
dormancy-inducing effects (49). This is also in agreement with the lack of preexisting
self-mRNA-targeting VI-B spacers in F. columnare B185 (n=7) (Fig. 4 and Table S3B).
However, this counterselection is much weaker than that against self-targeting II-C
spacers (Fig. 3B and C), which argues for a lesser effect of VI-B autoimmunity in this ex-
perimental setting. Saturation of phage mRNA-targeting VI-B spacers was not observed
here, which is likely due to the short time span of the experiment but may also be
affected by the preexisting, fully matching II-C spacers (Table S3A). If the preexisting
spacers already provide some level of CRISPR-Cas-based immunity, as suggested by
our plasmid interference assay, the need to acquire new ones is decreased, and their
selective advantage may be weaker.
Overall, the reasons for the unexpectedly low levels of mRNA-targeting spacers in
both CRISPR loci remain speculative. In this analysis, we relied on predicted ORFs and
do not take into account possible antisense transcription or intergenic transcripts; the
number of RNA-targeting spacers may therefore be underestimated. In contrast, in our
previous study on natural F. columnare isolates, there was a saturation of phage
mRNA-targeting VI-B spacers (n=19; P=1.9 1026 by a one-tailed binomial test)
(including the preexisting four spacers in the wild-type array of B185 [Table S3B]). Our
new results suggest that this was likely the result of positive selection toward mRNA-
targeting spacers. Interference by the VI-B system in nature is also supported by the
negative selection of targets: none of the preexisting VI-B spacers in strain B185 are
complete matches with their protospacers on the phage genome, and VI-B proto-
spacers accumulate mutations over time (34). Future studies are needed to assess how
RNA-based VI-B immunity evolves and what constitutes functional targets for VI-B in-
terference in native systems.
The VI-B array uses II-C Cas1 in trans. Identical spacer acquisition efficiencies, simi-
lar protospacer localization patterns, and shared PAM sequences supported the hy-
pothesis that the F. columnare subtype II-C and VI-B CRISPR-Cas loci share spacer acqui-
sition machinery. To verify this, we deleted cas1 from the subtype II-C locus from F.
columnare strain B245. Using the resulting B245 Dcas1 strain, we performed a pro-
longed adaptation experiment with 10 phage-exposed (phage V156) and 2 bacterium-
only replicates. As a control, we used a “reversion wild-type” (rev-wt) strain that
resulted from an alternative outcome of the mutation process and contains an intact
cas1 (see Materials and Methods). We did not observe spacer acquisition in either
CRISPR array in any of the 12 Dcas1 cultures (Fig. S4), all of which survived until the
end of the experiment. Of all 12 rev-wt cultures, only 2 phage-exposed replicates sur-
vived, both showing spacer acquisition in their II-C or VI-B arrays (Fig. S4). These results
demonstrate the dependence of the VI-B locus on the II-C acquisition machinery.
The inability of B245 rev-wt to survive in the presence of phages is in contrast with
the previous experiment performed with strain B185 and phage FCL-2. This difference
may partly stem from the experimental setups, as the bacterial strains B245 and B185
were cultivated in different media and for 3 weeks and 1 week, respectively (see
Materials and Methods). Also, strain B245 has four preexisting, fully matching phage
mRNA-targeting spacers in the variable end of the VI-B arrays (Table S3C and D),
whereas B185 has only incomplete VI-B spacer matches with its target, all located in
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the array’s conserved end. It is therefore possible that the B245 phage-targeting VI-B
spacers induce dormancy during the CRISPR-Cas response (49), whereas B185’s lack of
fully matching preexisting spacers does not. If this is the case, the survival of B245
Dcas1 is surprising as the inability to acquire new spacers should not abrogate interfer-
ence using preexisting ones. These strains also belong to different genetic groups, and
thus, their differences are not limited to spacer content. Further experiments to explore
the effect of spacer diversity and the role of different cas genes and other host
defenses in F. columnare are required.
Comparison of II-C/VI-B leaders and repeats across species. In F. columnare, sub-
types VI-B and II-C have similarly sized repeats (36 bp), with sequence similarity mostly
in the leader-distal ends (59-GTTGT-39) (Fig. 1). The lack of similarity in the leader-adja-
cent end of the repeat is surprising given the importance of this region during spacer
insertion, at least in the S. thermophilus subtype II-A system (26). The F. columnare lead-
ers also lack similarity in the leader-repeat junctions but share similarly positioned poly
(A) and poly(T) regions up to 100 bp from the junction (Fig. 1). To see if II-C and VI-B
CRISPR-Cas loci display similar patterns in other species, we extracted the repeats and
leaders of nine species that carry these loci (lacking cas1 and cas2 in their VI-B locus).
II-C and VI-B repeats shared the same leader-distal motifs across the species, but F. col-
umnare was the only species with similarly sized II-C and VI-B repeats (II-C repeats in
the other species were on average 11 bp longer) (Fig. S5). Leaders, clustered by Cas1
similarity for meaningful alignment, had leader-distal poly(A) and poly(T) motifs similar
to those of F. columnare (Fig. S6), which may act as binding or signaling sites for spacer
integration. As the generation of new repeats is based on a precise ruler mechanism in
the acquisition complex (15, 27, 61), it remains unknown how the other species with
differing repeat lengths generated their subtype VI-B arrays. It is therefore possible
that all or some of the subtype VI-B CRISPR-Cas systems in these species are inactive
and that F. columnare is one of the few or the only species engaging in cross talk
between VI-B and II-C systems. Indeed, subtype II-C adaptation was recently shown in
one of these species, Riemerella anatipestifer, but its cooccurring VI-B locus (denoted
an orphan array) did not acquire new spacers (62).
F. columnare CRISPR-Cas model. Based on our observations and previous bio-
chemical studies, we propose a model for F. columnare spacer acquisition and interfer-
ence. During acquisition, new spacers are captured by the Cas1/2 acquisition complex
(possibly aided by Cas9) in a specific conformation relative to the PAM (63, 64). This
prespacer is inserted into the array (15, 64–66), with the PAM end of the (proto)spacer
facing the leader (6, 67, 68). Leader recognition is probably mediated by shared motifs
in the subtype II-C and VI-B leaders and repeats that are distal from the leader-repeat
junctions. During interference, spacers produce a downstream interference-PAM (TIM)
in subtype II-C, as is generally observed in other type II systems (69). Since the arrays
are transcribed in opposite directions with respect to the variable end of the array
(Fig. 1 and Fig. S3), the TIM location is switched for subtype VI-B spacers during inter-
ference. Acquisition events relying on an identical SAM can therefore lead to two com-
plementary interference patterns, dictated by the array in which the spacer is inserted
(Fig. 6).
DISCUSSION
We demonstrate that a native subtype VI-B CRISPR-Cas locus acquires spacers from
a virulent dsDNA phage and from the host genome. Despite differences in repeat and
leader sequences, shared characteristics of the newly acquired spacers with the coad-
apting subtype II-C locus support the model of in trans spacer acquisition in the sub-
type VI-B locus, which was confirmed by analysis of a cas1 deletion mutant. This
arrangement provides the RNA-targeting VI-B array with an abundance of spacers that
do not target mRNA. Other species with similar CRISPR-Cas loci have more divergent
repeat sequences, suggesting that in trans acquisition may not occur in these species
or may utilize a highly plastic acquisition complex. This study also highlights F.
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columnare as one of the few known species that have been demonstrated to acquire
spacers from virulent phages under laboratory conditions (70).
Our conjugation assay suggested functional yet limited interference efficiency of
the II-C locus against plasmids, with a 3-fold reduction in conjugation efficiency.
Similarly, our previous study (34) showed that preexisting spacers do not grant F. col-
umnare efficient phage immunity. These results may be explained by suboptimal ex-
perimental conditions (i.e., high nutrient/phage concentrations) for testing interfer-
ence. Another possibility for low efficiency against phages may be phage-encoded
anti-CRISPR proteins (71). On the other hand, the lack of self-targeting II-C spacers in
this study suggests effective autoimmunity.
While our plasmid assay did not address VI-B interference, its role in actively target-
ing mRNA can be deduced by contrasting naturally acquired VI-B spacers with those
acquired in the laboratory: both mRNA- and DNA-targeting VI-B spacers were acquired
in the current study, but only mRNA-targeting spacers are observed in natural samples
of F. columnare (34), suggesting positive selection of such spacers under natural condi-
tions. Also, none of the preexisting VI-B spacers of F. columnare B185 (see Table S3B in
the supplemental material) are perfect matches with their targets, suggesting that
phages have previously escaped VI-B targeting, as also suggested by multiple natural
isolates (34).
We expect future studies to reveal the extent of cross talk in type VI systems and
the biochemical basis for the plasticity of the acquisition machinery when interacting
with different leader and repeat sequences. Possible priming in the II-C locus should
also be studied in detail, as should the interference stage of both loci, including the
possible dormancy-generating effects of the VI-B locus.
MATERIALS ANDMETHODS
Bacterial cultures and sampling. Two strains were used to test for CRISPR spacer acquisition:
Flavobacterium columnare B185 and B245 (34). Strain B185 was used as the host in the main spacer ac-
quisition assays, and strain B245 was used in the cas1 deletion mutant experiments. Strain B185 was
revived from a freezer stock in a Shieh medium culture grown overnight (72). Five replicates of 5-ml cul-
tures were then inoculated in 0.1 Shieh medium with the culture grown overnight to produce an initial
concentration of 104 CFU/ml. Phage FCL-2 (34) was added to the samples at a multiplicity of infection
(MOI) of 1. For the phage UV treatment (52), phage FCL-2 was exposed to UV light for 5 min on a petri
dish (5,000 mJ) (UV Stratalinker 1800; Stratagene), lowering the infectivity by roughly 2 orders of magni-
tude (data not shown). In the bacterium plus phage plus UV-phage treatments, wild-type phages were
mixed with an equal volume of UV-treated phages from the same stock and dilution. Five bacterium-
only and bacterium plus UV-phage cultures were established as controls. The cultures were incubated
under agitation (120 rpm) at room temperature for 5 days, after which they were transferred (1:100) to
FIG 6 Model for subtype II-C and VI-B interference in F. columnare. In this scenario, the leader-adjacent spacer of the II-C array is also present in the VI-B
array. However, due to opposite transcription directions, the crRNA is reversed and complementary between the loci. Mapping the crRNA onto the phage
genome using the guide-oriented approach (56) reveals a downstream TIM for II-C and an upstream “TIM” for VI-B (orange letters on the phage genome),
although the SAM is the same for both. All sequences shown here correspond to actual genomic sequences (except the VI-B spacer, which is the same as
the II-C spacer for illustration purposes). The relative orders of spacers/repeats in crRNA are derived from previous studies (39, 48).
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5ml of 1 Shieh medium. After 2 days (day 7 from the beginning of the experiment), cell debris had
sedimented at the bottom of the tubes. We sampled 1ml of the clear phase for living planktonic cells
and extracted DNA using a DNeasy blood and tissue kit (Qiagen). The cultures were also plated on Shieh
agar plates with 10-fold dilutions to estimate CFU per milliliter and to perform colony PCR.
Colony PCR. The variable ends of subtype II-C and VI-B CRISPR arrays were PCR amplified from colo-
nies obtained under all conditions (total of 281 colonies) at day 7 (see Table S1A in the supplemental
material) using primers C1_B185_F and C1_B185_R and primers C2_B185_F and C2_B185_R (Table S2A).
Colonies with expanded arrays were recultured on Shieh agar plates, and the variable ends of the
CRISPR arrays were rechecked. Colonies that still showed expanded arrays were grown in liquid medium,
the DNA was extracted with a blood and tissue kit (Qiagen), and the variable ends were sequenced with
the Sanger method using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems) and the
automated 3130xl genetic analyzer (Applied Biosystems) (Table S1B).
Population-level CRISPR deep sequencing. Total DNA was extracted from 1-ml liquid samples
using a DNeasy blood and tissue kit (Qiagen). The variable ends of subtype II-C and VI-B CRISPR loci (C1
and C2, respectively) from the phage and bacterium-only treatments were amplified with DreamTaq
(Thermo Fisher Scientific), with one primer binding to the leader sequence (C2_B185_F and C1_B185_R)
and one binding to the second (C1_B185_F) or third (C2_B185_R) spacer (Table S2A). The PCR protocol
to amplify the CRISPR array associated with subtype II-C was as follows: 95°C for 3min; 32 cycles of 95°C
for 30 s, 59°C for 30 s, and 72°C for 1min; and 72°C for 15min. The PCR protocol to amplify the CRISPR
array of subtype VI-B was as follows: 95°C for 3min; 30 cycles of 95°C for 30 s, 60.2°C for 30 s, and 72°C
for 1min; and 72°C for 15min. For subtype II-C, additional MgCl2 (4mM) was required for amplification.
To minimize PCR bias, four separate PCRs were performed for each of the five replicates, which were
then pooled and cleaned using a Qiagen MinElute reaction cleanup kit. The resulting 10-ml samples
were run on a 2% agarose gel (4.6 V/cm) for 2 h 45min in Tris-acetate-EDTA (TAE) buffer. The expected
PCR product sizes for the wild-type array (subtype II-C, 181 bp; subtype VI-B, 223 bp) as well as for the
expanded arrays with one new repeat-spacer unit (subtype II-C, 246 bp; subtype VI-B, 289 bp) were
extracted from the phage treatment using X-tracta (Sigma) extraction tools and a gel extraction kit
(Qiagen) using MinElute columns (Qiagen). In the bacterium-only treatments, the wild-type PCR prod-
ucts from both loci were extracted as controls. All extractions underwent two gel purification rounds to
reduce contamination.
For deep sequencing, we used the previously published pipeline for multiplexed Ion Torrent sequenc-
ing (4). The extracted PCR products from type VI-B were reamplified using Maxima Hot Start Taq DNA poly-
merase (Thermo Fisher Scientific), the primers M13-B185_223bp_C2F and P1-B185_223bp_C2R, as well as
the IonA_bc_M13 primer that contained multiplexing barcodes and an M13 adaptor (Table S2A) (73). The
following PCR program was used: 95°C for 5min; 20 cycles of 94°C for 45 s, 53°C for 1min, and 72°C for
1min; and 72°C for 5min. As we were unable to obtain amplification of the type II-C array with the above-
described three-primer PCR approach, the PCR was split into two stages. First, type II-C PCR products were
amplified using the primer pair M13-B185_C1_F3/P1-B185_181bp_C1R and the DreamTaq enzyme with
added MgCl2 (4mM) using the following program: 95°C for 5min; 31 cycles of 95°C for 30 s, 59°C for 30 s,
and 72°C for 1min; and 72°C for 15min. The reaction mixture was then purified with Agencourt AMPureXP
(Beckman Coulter) and reamplified using primers IonA-bc_M13 (73) and P1-B185_181bp_C1R in a reaction
identical to the three-primer reaction used for type VI-B. Finally, all samples were purified using AMPureXP
and quantified with a Qubit fluorometer and a Qubit dsDNA HS kit. Equimolar amounts (5ng) of PCR prod-
ucts were pooled for sequencing. Pooled PCR products were sequenced after emulsion PCR with the Ion
OneTouch system and Ion OT2 400 kit (Life Technologies) on Ion 314 chips with the Ion PGM (personal ge-
nome machine) sequencing 400 kit (Life Technologies), according to the manufacturer’s instructions.
Deep sequencing data preparation. Nontrimmed reads were obtained from PGM and sorted by
their barcodes. Trimmomatic 0.36 (74) was used for quality control with the following parameters:
SLIDINGWINDOW:3:21, MINLEN:100, and TRAILING:23. Spacers were extracted from the trimmed reads
using a custom Python script that extracted 27- to 32-bp spacers between an intact first repeat and the
first 4 nucleotides of the subsequent repeat. Due to short reads, a fully intact second repeat was usually
not available. To obtain unique spacers, each spacer pool was clustered with CD-hit-est (75) using a clus-
tering threshold of 0.8 and a word size of 5. The resulting spacers before and after filtering are listed in
Table S2B.
Mapping. The spacers were mapped to the previously published phage genome (59) using Bowtie
2.0 (76) with the following custom configuration: –very-sensitive-local –score-min G,10,8. The physical
ends of the linear phage genome had been determined previously using a combination of next-genera-
tion sequencing and Sanger sequencing (59). Unmapped spacers were then mapped onto the bacterial
genome, and the remaining unmapped reads (most probably due to poor sequence quality) were dis-
carded. On average, 7.9% and 1.14% of unique spacers were discarded in the type II-C and VI-B loci,
respectively. The genomes were divided into bins that span 3% of the respective genomes, and the pro-
tospacer count of each bin was calculated with a custom Python script. The resulting protospacer distri-
bution on both genomes was illustrated using the ggplot2 package in RStudio 1.1.463 (R 3.5.3). The pre-
dicted origin of replication (oriC) region of F. columnare was determined using DoriC 10.0.0 (77).
PAM sequences. With the aim of comparing PAM sequences between the loci, we report all PAM
sequences based on flanking DNA (instead of RNA) regions due to the large proportion of only-DNA-tar-
geting type VI-B spacers. Similarly, we follow the guide-oriented approach for both loci, as is common
with DNA-targeting systems (56) (PAM is depicted on the noncomplementary strand with respect to the
crRNA). All PAM sequences were extracted using custom Python scripts and shown using WebLogo (78).
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Spacer pool identity level analysis. To calculate the proportion of subtype VI-B spacers that are
identical to II-C spacers, unique VI-B spacers from all replicates (b, d, and e) were first pooled. CD-hit-est
was used to extract unique spacers from the pooled spacer set (clustering threshold of 0.8). The process
was repeated for the type II-C spacers from replicates b and e. Next, the pooled unique spacer sets from
both loci were compared to each other with CD-hit-est-2D using a similarity threshold of 0.9. The num-
ber of resulting clusters was then used to calculate the proportion of VI-B spacers that had a match in
the type II-C spacer pool. Simulated sets of 430 spacers (the number of unique VI-B spacers pooled from
all three replicates) were generated by sampling the phage genome either at random positions or from
the 1,672 predicted PAM sites (59-NNNNNTAAA-39). Sampling was repeated 1,000 times, and similarities
of the simulated spacers were compared with the type II-C spacer pool using CD-hit-est-2D as described
above. A normal distribution was fit onto the simulated distributions using the R function fitdistr from
the MASS package. The probability of the observed similarity, given the null hypothesis, between sub-
type II-C and VI-B spacers (0.58) was measured using the function pnorm from the upper tails of the
distributions.
Proportions of mRNA-targeting spacers. The ability of each spacer to target an ORF’s transcript
was determined by two rules: (i) the crRNA of the spacer must be complementary to the coding strand,
and (ii) the protospacer must be fully contained within an ORF. Intergenic spacers were excluded from
the analysis. The number of mRNA-targeting spacers was divided by the total number of ORF-targeting
spacers in the sample to obtain the proportion of mRNA-targeting spacers for each replicate separately.
We also performed the analysis for pooled spacers from the replicates. Pools were made on the basis of
locus and target, resulting in four pools (II-C phage, II-C self, VI-B phage, and VI-B self).
The mRNA proportions from pooled spacers were compared to a null hypothesis that assumed an
equal chance of a spacer targeting both strands. Since intergenic spacers were excluded from the analy-
sis, a binomial distribution could be used to construct the model. Separate distributions were created
for each spacer pool to account for different numbers of spacers in each. The observed values in both
loci were then compared to their respective distributions to yield direct P values on their probability
given the null hypothesis described above (one-tailed test using the pbinom function in R). This analysis
was done separately for the unique and absolute spacer counts.
RNA-seq and transcription direction. The direction of CRISPR array transcription was determined
from bacterial RNA sequencing (RNA-seq) data. F. columnare B185 was grown without phages in 10ml
of Shieh medium at 24°C with constant shaking at 150 rpm. Next, 24-h-grown cultures (optical density
[OD] of 0.166 to 0.203) were centrifuged (5,000 rpm) and stored in RNAlater (Qiagen), until RNA was
extracted with an Ambion MicrobExpress mRNA purification kit. RNA quality was verified using an
Agilent Bioanalyzer 2100 RNA nanochip, and samples with RNA integrity values of .9.5 were selected
for library preparation (Ion Total RNA-seq kit v2). The cDNA was sequenced with Ion Torrent using a 318
chip (v2) and an internal ERCC (External RNA Controls Consortium) spike-in control, after ensuring cDNA
quality (Agilent Bioanalyzer 2100 DNA high-sensitivity chip). Our results support previous reports show-
ing type VI-B crRNA transcription from the leader end (39) and type II-C transcription toward the leader
end (starting from within each repeat) or the leader-distal end of the array (48) (Fig. S3). The RNA sam-
ples for this analysis were taken from three pooled cultures of F. columnare B185 in the absence of
phages, showing that these arrays are expressed constitutively albeit at a very low level (reads mapping
on arrays at 167.8 and 986.6 reads per million in II-C and VI-B, respectively).
cas1 deletion mutant. Not all F. columnare strains accept plasmids by conjugation (54). As strain
B185 was unable to receive plasmids via conjugation or electroporation (data not shown), we used strain
B245 (34) to create the cas1 deletion mutant Dcas1. Due to its competence in plasmid conjugation,
strain B245 was also used in the plasmid interference assay described below. The 2.1-kbp region
upstream of cas1 was amplified by PCR using Phusion DNA polymerase (New England BioLabs) and pri-
mers 2322 (adding a KpnI site) and 2323 (adding a BamHI site). The PCR product was digested with KpnI
and BamHI and ligated into the plasmid pMS75 (79) that had been digested with the same enzymes, to
produce pRC30. A 495-bp region downstream of cas1 was PCR amplified using primers 2324 (adding a
BamHI site) and 2325 (adding a SalI site) (Table S2A). The PCR product was digested with BamHI and SalI
and ligated into pRC30 that had been digested with the same enzymes, to generate pRC32. The plasmid
pRC32 was transferred from E. coli S17-1lpir into F. columnare strain B245 by conjugation. One milliliter
of a culture of the recombinant E. coli strain grown overnight was inoculated into 9 ml of LB containing
100mg/ml ampicillin and incubated with shaking at 37°C until the OD at 600 nm (OD600) reached 0.6.
Similarly, 5 ml of a culture of F. columnare B245 grown overnight was inoculated into 25ml fresh TYES
(tryptone yeast extract salts) broth (80) and incubated at 28°C with shaking, until the OD600 reached 0.6.
The E. coli and F. columnare cells were centrifuged separately at 5,000 rpm for 15 min, and the pellets
were washed with 10ml of TYES medium and centrifuged at 5,000 rpm for 10 min. The E. coli and F. col-
umnare cell pellets were each suspended in 0.8ml of TYES medium, mixed, and centrifuged at 7,000 rpm
for 3 min. Excess medium was removed, and the mixed pellet was suspended and spotted on FCGM
(Flavobacterium columnare growth medium) agar medium (80). After incubation at 30°C for 24 h, cells
were scraped off the plate and suspended in 1.5ml of TYES medium. Next, 100-ml aliquots were spread
on TYES agar containing 1mg/ml tobramycin and 5mg/ml tetracycline and incubated at 30°C for 72 h.
The resulting tetracycline-resistant colonies were streaked for isolation, inoculated into TYES liquid me-
dium without tetracycline, and incubated overnight at 25°C with shaking to allow plasmid loss. The cells
were plated on TYES medium containing 10% sucrose, incubated at room temperature (20°C) to select
for the lack of sucrose toxicity, and streaked for isolation using the same selection. The cas1 deletion
was screened by PCR and gel electrophoresis and verified with Sanger sequencing using primers Cas1_F
and Cas1_R. All primers used are listed in Table S2A.
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Strains used in the new spacer acquisition experiment were Dcas1 and B245_rev (rev-wt). The latter
is a reversion mutant where the integrated plasmid was lost by recombination in a manner that regener-
ated the wild-type sequence. Phage V156 (34) was used to trigger spacer acquisition. The infectivity of
phage V156 against the two hosts (Dcas1 and rev-wt) was measured with a standard double-layer
method, where 300ml of a turbid bacterial culture was mixed with 3ml of TYES medium with 0.1%
mucin and 1% agar. The mixture was poured onto a TYES agar plate, and 10ml of phage V156 dilutions
(1021 to 1027) were spotted in duplicates onto the solidified agar. The number of plaques was counted
after 2 days from the 1027 dilutions. Phage titers (PFU per milliliter) were 1.9 1010 and 3.7 1010 on
the Dcas1 and rev-wt strains, respectively.
For the spacer acquisition experiment, both strains were grown overnight in single 5-ml cultures to
reach an OD600 of 0.45. Ten phage-infected cultures in 0.1 TYES medium as well as two bacterium-only
cultures were started from these cultures grown overnight. The spacer acquisition protocol differed
from the one used with B185, as follows: medium TYES (versus Shieh medium), volume of 1ml (versus
5ml), and duration of growth in 0.1 medium of 3 weeks (versus 5 days). The protocol was prolonged
because follow-up experiments showed that longer incubation in diluted medium resulted in more effi-
cient spacer acquisition. The medium or its volume has no detectable effect on the acquisition efficiency
(data not shown) and was changed for practical reasons. After 3 weeks in diluted medium (0.1), the
cultures were transferred to regular TYES medium (1), and the CRISPR arrays were PCR amplified after
2 days. All 12 phage-containing cultures of the Dcas1 strain showed growth in 1 medium, in contrast
to only 2 of 12 replicates of the rev-wt cultures. The variable ends of both CRISPR arrays in all surviving
cultures were PCR amplified using primers B245_C1_F and F_col_C1_R (B245 II-C array) and primers
F_col_C2_F and B245_C2_R (B245 VI-B array) (Table S2A and Fig. S4).
Plasmid interference assay. A derivative of plasmid pAS43 (54) (with a removed KpnI restriction
site, not relevant to this experiment) was used as a template for adding a protospacer sequence fol-
lowed by the putative PAM sequence 59-NNNNNTAAA-39. Two plasmids were constructed: one with a
protospacer matching the most recent II-C spacer (next to the leader sequence) of F. columnare strain
B245 (GGTAATTTTAAAACAAATGAGTATGTACGAACTGCTAAA [the PAM sequence is underlined]) and one
with a nonmatching control sequence (ATCAGATCTAATCTCTATGTCAATGTATGAACTGCTAAA [the PAM
sequence is underlined]). The insertions were added to the plasmid at an intergenic multiple-cloning-
site region using the Q5 site-directed mutagenesis kit (New England BioLabs) and the oligonucleotide
pair pAS43_protoSDM_F/R (matching protospacer) or pAS43_protoSDM_neg_F/R (nonmatching proto-
spacer) (Table S2A). The initial PCR was done using Phusion polymerase with 3% dimethyl sulfoxide
(DMSO) using the following program: 98°C for 10 s and 24 cycles of 98°C for 1 s, 60°C for 7 s, 72°C for
12min, and 72°C for 15min. The amplified product was inspected on an agarose gel and subjected to
downstream KLD (kinase, ligase and DpnI mix) treatment according to the mutagenesis kit instructions.
The resulting plasmid was transformed into chemically competent E. coli strain S17-1lpir. Successful
transformation and insertion were verified by colony PCR and Sanger sequencing (primer pair
pAS43_MCS2_seq_F/R) (Table S2A).
In the quantitative conjugation assay, the plasmids were transferred into F. columnare strain B245.
Both the donor and the recipient cells were first grown overnight from a freezer stock. The turbid cul-
tures were then transferred to fresh medium (LB for E. coli and TYES medium for F. columnare). E. coli
was grown to an OD600 of 0.95, and the recipient F. columnare strain was grown to an OD600 of 0.414.
The conjugation protocol was performed similarly to the cas1 deletion (described above), and the final
donor/recipient mixtures were spotted on 0.45-mm filters resting on FCGM plates. After 24 h of growth
at 30°C, the cells were scraped from the filters and resuspended in 2ml TYES liquid medium. Next,
150ml of the mixed cultures was plated on double-antibiotic selection plates without dilution (cefoxitin
for conjugant selection and tobramycin for eliminating E. coli) as well as on tobramycin-only plates with
1025 and 1026 dilutions for determining the number of potential recipient cells in each replicate (F. col-
umnare is naturally resistant to tobramycin). Colonies were counted and plates were photographed after
72 h at 25°C. The efficiency of conjugation was determined by dividing the number of F. columnare con-
jugants (double-selection plate) by the number of potential recipients (tobramycin plates) in each
replicate.
Comparison of type II-C and VI-B leaders and repeats in other species. Microbial species that
carry intact subtype II-C (containing cas1, cas2, cas9, and a CRISPR array) and VI-B (containing cas13b and
a CRISPR array) loci were identified using CRISPRCasdb (81), and one strain per species was selected for
further analysis (Flavobacterium branchiophilum was excluded from the analysis due to the absence of
cas1 in the subtype II-C locus). From each strain, repeat sequences from both loci were aligned with
Geneious aligner (global alignment with free gaps, 51% cost matrix, gap open penalty of 12, and gap
extension penalty of 3). Next, 200-bp leader sequences were extracted downstream of the expected vari-
able end of the array. The variable ends were primarily determined by the repeats’ direction compared
to F. columnare strain B185. These initial predictions were supported by the presence of possible degen-
erate terminal repeats and alignment scores of both flanking regions compared to the leader of F. col-
umnare B185. To allow the comparison of the highly divergent leaders, the strains were first clustered
based on their Cas1 protein (Jukes-Cantor, unweighted pair group method using average linkages
[UPGMA]). The leaders from both loci within the resulting six clusters (most of which contained single
species) were aligned with Geneious aligner (global alignment, 65% cost matrix, gap open penalty of 17,
and gap extension penalty 12). We used strict alignment rules to emphasize the importance of the dis-
tance of possible motifs from the repeat-leader junction. Analyses and alignments were performed with
Geneious 9.1.8.
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Data availability. The B245 genome and raw reads from the spacer acquisition experiment have
been submitted to GenBank under accession numbers CP071008 and SAMN18022999, respectively. The
genomes of F. columnare strain B185 (accession no. NZ_CP010992.1) and phage FCL-2 (accession no. NC
_027125.1) are available in GenBank. Custom code and instructions for analyzing the raw data and
reproducing all figures in the manuscript are in GitHub at https://github.com/vihoikka/spacerAQ_vh.
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